Literature DB >> 21196364

Vulvar cancer as a target for molecular medicine.

Aleksandra Klemba1, Wojciech Kukwa, Andrzej Semczuk, Anna M Czarnecka.   

Abstract

Vulvar carcinoma is a rare female genital neoplasm. Although numerous molecular defects in vulvar carcinomas have been reported until now, no molecular markers that could be applied in daily clinical work have been identified so far. However, there is emerging evidence that specific mutations and gene expression patterns may be used as diagnostic tools in oncology. In this article we systematically review genetic alterations that may contribute to the development and progression of vulvar carcinoma. We conclude by suggesting molecular markers of potential clinical value in the diagnostics of this type of cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196364     DOI: 10.2741/s139

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  3 in total

1.  Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.

Authors:  André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Beatriz de Melo Maia; Mônica Maria Ágata Stiepcich; Glauco Baiocchi; Kátia Cândido Carvalho; Fernando Augusto Soares; José Vassallo; Rafael Malagoli Rocha
Journal:  Tumour Biol       Date:  2013-07-06

2.  Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma.

Authors:  David K Gaffney; Bronwyn King; Akila N Viswanathan; Maroie Barkati; Sushil Beriwal; Patricia Eifel; Beth Erickson; Anthony Fyles; Jennifer Goulart; Matthew Harkenrider; Anuja Jhingran; Ann Klopp; Wui-Jin Koh; Karen Lim; Ivy Petersen; Lorraine Portelance; William Small; Alexandra Stewart; Ericka Wiebe; Aaron Wolfson; Catheryn Yashar; Walter Bosch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-21       Impact factor: 7.038

3.  Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana.

Authors:  Kenneth O Simbiri; Hem C Jha; Mukendi K Kayembe; Carrie Kovarik; Erle S Robertson
Journal:  Infect Agent Cancer       Date:  2014-08-24       Impact factor: 2.965

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.